Patrick Gorman, MD
Cardiovascular Disease · Idaho Falls, IDNPI 1295735769
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 207 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Boston Scientific at 45.0% of the total. Reporting peaked in 2023 at $791 and has fallen 61.8% since, to $302 in 2025.
Across 207 payments — averaging $17.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Abbott$640
- Novartis$450
- Medtronic$434
- Abiomed$109
- Baxter Healthcare$44
- plus $263 from 12 others
What the payments were for
- Food & beverage$3,530100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 101 | $1,590 |
| Abbott | 35 | $640 |
| Novartis | 36 | $450 |
| Medtronic(2 entities) | 16 | $434 |
| Abiomed | 2 | $109 |
| Baxter Healthcare | 2 | $44 |
| Amarin Pharma, Inc. | 2 | $39 |
| Pfizer | 2 | $35 |
| E.r. Squibb & Sons, L.L.C. | 2 | $33 |
| GE HealthCare | 1 | $30 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $18 |
| Philips North America LLC | 1 | $17 |
| Acutus Medical, Inc. | 1 | $16 |
| Scpharmaceuticals Inc. | 1 | $15 |
| Altathera Pharmaceuticals LLC | 1 | $14 |
| Bardy Diagnostics, Inc. | 1 | $14 |
| Actelion Pharmaceuticals US, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Micra$133
How this compares
$3,530 in reported general payments places this provider in the 60th percentile of 59 cardiovascular disease providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 758 | $740,490 |
| EntrestoSacubitril/Valsartan | 163 | $151,137 |
| XareltoRivaroxaban | 144 | $129,328 |
| FarxigaDapagliflozin Propanediol | 57 | $42,345 |
| Repatha SureclickEvolocumab | 37 | $29,542 |
| Flecainide Acetate | 298 | $28,428 |
| JardianceEmpagliflozin | 15 | $24,110 |
| Prasugrel Hcl | 140 | $21,853 |
| SotalolSotalol Hcl | 969 | $21,752 |
| OzempicSemaglutide | 18 | $17,531 |
| MyrbetriqMirabegron | 22 | $16,951 |
| MultaqDronedarone Hcl | 12 | $16,603 |
| Repatha SyringeEvolocumab | 19 | $12,280 |
| Atorvastatin Calcium | 984 | $9,162 |
| Potassium Chloride | 378 | $8,995 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $35 | $740,490758 claims |
| NovartisEntresto | $450 | $151,137163 claims |
| Johnson & JohnsonXarelto | $18 | $129,328144 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 59 cardiovascular disease providers in Idaho.
Other cardiovascular disease in Idaho Falls
- Douglas BlankIdaho Falls$11K
- John ChambersIdaho Falls$8K
- John LassetterIdaho Falls$6K
- Paul GerlachIdaho Falls$6K
- George GarciaIdaho Falls$6K
- Ricky LathamIdaho Falls$2K
- Thomas MaleyIdaho Falls$35
- Kim CoffmanIdaho Falls$12
- David HinchmanBoise$324K
- Jacob DelarosaPocatello$226K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.